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Animals vaccinated with living Calmette-Gudrin bacillus (BCG)  are known 
to be significantly more resistant to virulent mycobacteria than are nonvac- 
cinated animals. Nonetheless,  despite  the  unequivocal effectiveness of  BCG, 
little is known about the nature of antitubercular resistance, and widespread 
controversy  exists  in  ahnost  all  practical  aspects  concerning the  induction, 
development, and persistence of immunity both in experimental animals and 
in man. 
Several lines of experimental evidence gathered  in our laboratory over the 
last several years yield information concerning these matters. Hence,  a  brief 
summary of our findings is given in this and subsequent papers. The first line 
of evidence to be dealt with concerns the  comparative effectiveness of  living 
vaccines against different types of experimental tuberculous infections. These 
studies will be described herein, and in an accompanying paper. 
Materials and Methods 
Animals.--The  NCS strain of Swiss albino mice were used in the majority of experiments 
in this study (1). COB S  1  strain pathogen-free mice were used in a few experiments. The results 
obtained with animals of either mouse strain were essentially identical and the results described 
in this paper will be limited to the findings obtained with NCS mice. 
Details of animal husbandry have been previously described (2, 3). Female animals were 
used in all experiments. Mice were obtained when 4-6 wk of age. Groups of 20 animals were 
used for mortality experiments and were maintained in cages with wire grid bottoms. Groups 
of 5 animals were used for all other experiments and were maintained in polycarbonate cages 
* This  investigation  was  supported  in part  by the  United  States-Japan  Cooperative 
Medical Science Program administered by the National Institute of Allergy and Infectious 
Disease of the National Institutes of Health, Department  of Health, Education, and Welfare. 
2~ Portions of this work were undertaken during the tenure of a World Health Organization 
Fellowship by Dr.  Izumi. 
§ Present  Address: Institute of  Research for Tuberculosis and  Chest  Diseases, Kyoto 
University, Sakyo-Ku, Kyoto, Japan. 
1  Caesarian Origin Barrier Sustained Swiss strain mice were obtained from Charles River 
Breeding Laboratories, North Wilmington, Mass. 
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with sawdust bedding. Iso-cap  ® (Lab Cages Inc., Kennett Square, Pa.) barriers were routinely 
used on these cages. All cages were changed weekly. 
Animals were maintained on D  & G pellets (Dietrich & Gambrill Inc., Frederick, Md.) 
unless otherwise stated. Animals were given tap water ad libitum. Water bottles were changed 
thrice weekly. 
Organlsms.--The  several strains of organisms used in these studies are briefly described 
below. 
BCG.--(a)  The  Montreal strain of BCG was obtained from the Institute of  Hygiene, 
University of Montreal, Montreal, Canada. In preliminary experiments a  culture obtained 
from the surface of egg medium was transferred into Tween-albumin medium, grown at 37°C 
for 7 days, and subsequently maintained at 4°C. Subcultures from this stock were made in 
Tween-albumin medium. (b) Ampules of lyophilized BCG (Montreal strain) containing large 
quantities of bacilli were generously supplied by Dr. A Frappier of the Institute of Hygiene 
of  Montreal and used in the majority of the experiments. Vials of vaccine (Lot No.  1364-4) 
contained 112  mg dried organisms per ampule and were reconstituted with albumin water. 
The vaccine was used without subculture.  (c) The Phipps strain of BCG, used in a  limited 
number of experiments, was a  stock culture originally described in reference 4.  Subcultures 
were made in Tween-albumin medium and grown for 7 days. 
Mycobacterlum  Tuberculosis.--The  H37Rv  strain of M.  tuberculosis was obtained from 
The Trudeau  Foundation Laboratories, Saranac Lake, N.Y.  in  1967. The organisms were 
transferred to Kirchner's medium with Tween albumin (5)  on receipt. Cultures were main- 
tained at  4°C. Transfers were made from this stock immediately preceding use.  For this 
purpose, 2  ml of the stock culture was transferred to 20  ml of  Kirchner's Tween-albumin 
medium and incubated at 37°C for 5 days. A second transfer of 2 ml of this growth to 20 m 
of Kirchner's medium without albumin was made and incubated for a  further 5 days. At 
this time the culture  had  an optical density of 0.230-0.250  and  contained approximately 
8  X  106 viable units/ml. 
In recent experiments comparative tests have been made with a  strain of H37Rv newly 
obtained from The Trudeau Laboratory (Lot No. TMC102). The results obtained with either 
subculture were essentially the same. 
Vaccination.--Mice  were vaccinated by peritoneal injection of the BCG strains previously 
described. Dilutions of vaccine were made in albumin water. Injections were in a final volume 
of 0.2 ml. 
Challenge Infection.--The mortality test described by Donovick et al.  (6)  was used with 
but limited modification. Mice were infected by intravenous injection (caudal vein) of 0.2 ml 
of the undiluted inoculum of H37Rv grown as described above. 
BCG Infection.--The in vivo growth of vaccine bacilli  in lungs and spleens of mice was 
determined follwoing  administration by  the peritoneal, intravenous, or  respiratory  route. 
Dilutions of vaccine were made in albumin water. Peritoneal or caudal vein injections were in 
a final volume of 0.2 ml. 
For respiratory vaccination ampules of lyophilized BCG were utilized. Each ampule was 
reconstituted with 5 ml of water and the sample was homogenized in a  glass Teflon tissue 
grinder for  exactly  1  rain.  The  suspension was  filtered through a  presterilized Millipore 
Monitor Filter  ® (Millipore  Corporation, Bedford, Mass.) of 5/z pore size.  10-15  ml of sus- 
pension were passed through one individual filter. Inocula prepared in this manner consisted 
primarily of single cells  suitable for aerosol administration. Material sufficient  for several 
vaccinations was prepared at one time and stored at --60°C until use (7). 
Animals were vaccinated in a  Middlebrook-type aerosolization chamber  (Tri  R  Instru- 
ment Corporation, Rockville Center, N.Y.)  (8).  10 ml of undiluted vaccine suspension was 
nebulized over a 60 min period. The rate of infectious air flow was held constant at 20 liters/ 364  TUBERCULOSIS RESISTANCE 
min. Following nebulization of the infective inoculum, the aerosol cloud was allowed to decay 
for 30 min, and the chamber was decontaminated with UV light for a further  15 rain period. 
Enumeration of Organisms.--Animals were sacrificed by cervical dislocation or  by  CO2 
anesthesia. Spleens and lungs were aseptically removed. The organs were homogenized in 2% 
bovine serum albumin water with the aid of a Teflon-glass tissue grinder. Serial 10-fold dilu- 
tions were made in albumin water. Samples of each dilution were transferred to sterile screw 
cap tubes to which 2 ml of base medium containing 0.2% agar was added. The base medium 
commonly utilized in these experiments had the following compsition (9) : Na2HPO4-12H20, 
3.0 g; KH2PO4 (Anhyd.), 4.0 g; sodium citrate, 1.0 g; ferric ammonium citrate  (brow~), 
0.1 g; MgSO4.TH~O, 0.1 g; Bacto asparagine, 2.0 g; Bacto tryptone, 5.0 g; Bacto agar, 2.0 g; 
glycerin, 10.0 ml, and water to 1000 ml. The following additions were made to each 100 ml 
of melted medium immediately before use; penicillin (10,000 units/ml), 0.1  ml; lysozyme 
(0.1% in 0.01 7,1 HCI), 1.0 ml; bovine serum, 10.0 ml. The tubes were incubated at 37°C and 
the number of colonies developing therein was determined after 3 wk incubation. 
RESULTS 
The most dramatic evidence for the existence of antitubercular immunity is 
the marked prolongation of survival of vaccinated animals intravenously chal- 
lenged with virulent bacilli. Despite the apparent simplicity of such mortality 
studies, however,  almost nothing is known about the factors involved in  this 
type of protective resistance. Indeed, even the relation between the  develop- 
ment of the vaccinal population and the length of prolongation of  survival has 
seldom been studied and is poorly understood. This matter is directly investi- 
gated in the experiments to be described. 
Development of BCG in  Organs of Mice.--The  intra-organ development of 
BCG administered by the peritoneal route was initially determined in prelimi- 
nary experiments. 
To this end standardized preparations of lyophilized vaccine were used. Typically, a large 
number of female mice were obtained and randomly apportioned into several groups. Each 
group of mice was injected by the peritoneal route with 0.2 ml of a serially diluted  sample 
of freshly reconstituted  vaccine. At subsequent intervals  thereafter  representative  animals 
were sacrificed, their lungs and spleens aseptically removed, and the number  of BCG organisms 
present in these tissues determined. 
In the first experiment detailed in Table I, 6-wk old female mice were used. 
Individual animals in different groups received 0.2 ml of vaccine containing, 
respectively, 10 ~'6, 104.6, or 103 ,6 cultivable bacilli. The number of bacilli present 
in the animals' lungs and spleens were determined 24 hr after infection and at 
intervals thereafter. 
The results of a  second similar experiment are also detailed in Table I. In 
this experiment, a wider range of BCG inocula was used and the animals were 
observed for longer periods of time. Since the results of the two experiments 
were essentially the same, they will be discussed together. 
As may be seen in Table I, large numbers of BCG organisms were recovered 
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cine  organisms  were  widely  distributed  throughout  the  animals'  organs  im- 
mediately after their peritoneal administration.  The average number  of bacilli 
recovered from the animals'  organs  at  all times after vaccination was directly 
related to the size of the vaccinating dose. 
BCG Or 
Experi- 
ment* 
TABLE I 
anisms Recovered from Organs  of Mice at Various Times after Peritoneal Vaccination 
rim 
dte 
nje~ 
tior 
clay 
1 
3 
7 
14 
28 
42 
wk 
1 
4 
lO 
20 
Number of bacilli  present in organs (log) 
10  5.6 BCG cells injected  10  4.6 BCG cells injected  10  3.6 BCG cells injected 
Spleen  Lung  Spleen  Lung  Spleen  Lung 
4.9  4-  0.48 
5.0  4-  0.32 
4.3  4-  0.53 
4.0  4-  0.44 
3.8  4-  0.37 
2.6  4-  0.49 
1.6  4-  0.02 
2.6  4-  0.42 
2.2  -4-  0.28 
1.6  4-  0.41 
1.7  4-  0.17 
0.2  (2/5) 
3.4  4-  0.17 
3.5  4-  0.24 
3.7  4-  0.33 
3.0  4-  0.16 
3.1  4-  0.32] 
2.0  4-  0.36 
1.3  4-  0.19 
1.4  4-  0.28 
1.1  4-4- 0.31 
0.7  4-  0.25 
0.8  4-  0.13 
0.1  (2/5) 
2.18  4-  0.0~ 
2.54  4-  0.10 
2.5  4-  0.65 
2.6  4-  0.36 
2.0  4-  0.28 
N.D. 
N.D. 
0.92  :t=  0.25 
0.50  4-  0.28 
0.34  4-  0.10 
0.6  (1/5) 
N.D. 
105.~ BCG cells injected  103 -~ BCGcells injected  101.~BCG cells injected 
Spleen  Lung  Spleen  Lung  Spleen  Lung 
1.9  +  0.38 
1.2  +  0.58 
0.3  4-  0.19 
0.1  (1/5) 
3.0  4-  0.16 
3.3  4-  0.34 
3.1  4-  0.52 
2.2  4-  0.66 
0.7  4-  0.18 
0.3  (1/5) 
0.2  (1/5) 
o.o  (o/5) 
0.0  (0/5) 
0.0  (0/5) 
0.4  (4/5) 
0.4  (1/5) 
3.9  4-  0.22 
3.9  4-  0.31 
3.8  4-  0.37 
3.2  4-  0.53 
0.0  (0/5) 
0.3  (1/5) 
0.5  (1/5) 
0.5  (1/5) 
N. D. indicates that  values were not determined. 
* Mice in experiment No. one were 42  days old when vaccinated with BCG; in experi- 
ment  No.  two they were  35  days  old. 
$ No. of bacilli  (log) present in 1 ml  (out of 5)  of organ homogenate at indicated time 
after injection of Montreal strain BCG 4- s~ of mean. Values in parentheses refer to number 
of organs positive out of total number tested. Otherwise values are arithmetical average of 
five organs. 
As shown  in Table I, the number  of organisms present  within splenic tissue 
24  hr  after  vaccination  was  roughly  proportional  to  the  number  of  bacilli 
initially injected  in  an  animal's  peritoneal  cavity.  Although  fewer  organisms 
were taken  up by pulmonary  tissue,  the initial pulmonary  population  of BCG 
was also related to the size of the vaccinating dose. 
No  significant  multiplication  of  BCG  occurred  in  either  tissue.  24 hr  after 
4  infection, for example,  approximately  7  X  104 BCG  organisms were recovered 366  TUBERCULOSIS  RESISTANCE 
from spleens of animals infected with  the largest quantity of BCG. No more 
than 10  X  104 bacilli were recovered from the spleens of these animals at any 
subsequent time. Mice receiving smaller numbers of B CG responded in a similar 
fashion. Thus, spleens of mice injectedwith 103.6 BCG bacilli were found to con- 
tain an average of 150 vaccinal organisms in their spleens 24 hr after infection; 
no more than 400 bacilli were ever recovered from animals in this group. 
Somewhat surprisingly, it was found that the splenic population of BCG did 
not appreciably diminish with time. As shown by the results of experiment 2, 
the number  of vaccinal organisms present  20  wk  after vaccination were not 
strikingly lower than those obtained 1 wk after BCG injection.  For example, 
an average of 8000 BCG were recovered from spleens of animals receiving 105.2 
BCG organisms 1 wk after infection. 20 wk later spleens of these animals still 
retained an average of almost 2000  BCG bacilli. 
This persistence of vaccinal organisms extended  over long periods  of time. 
In several experiments it was found that B CG bacilli were still present in splenic 
tissue of mice 1 yr after peritoneal injection of vaccine. 
A similar lack of vaccine multiplication was found in pulmonary tissues. In 
contrast to the findings with splenic tissue,  however, vaccine organisms were 
slowly eliminated from pulmonary tissue and eventually this organ became free 
of cultivable bacilli. 
Similar results have been found in a large number of experiments performed 
under a variety of experimental conditions over a period of several years. The 
results  of such  experiments  can  be  briefly summarized  as follows.  Montreal 
strain BCG administered by the peritoneal route consistently initiated  a per- 
sistent splenic infection from the outset of administration of the vaccine. The 
number of bacilli present in the spleens were maintained without appreciable 
multiplication or destruction for significant periods of time. Furthermore,  the 
size of the splenic infection was proportional to and partially determined by the 
size of the vaccinal dose. 
Thus  it appears that BCG injected  into mice by the  intraperitoneal route 
behaved much as a living but nonmultiplying antimycobacterial vaccine. 
The conditions affecting the acquisition of vaccinal dormancy by intraperi- 
toneally  injected  BCG were  studied  more closely in  other  experiments.  The 
results of these studies are briefly detailed in the next sections. 
Comparative Behavior of Peritoneally  Injected  Phipps  Strain  BCG.--BCG 
strains are known to differ in their ability to multiply in vivo. It was therefore 
of interest to determine whether the ability to persist in the dormant state was 
peculiar to the Montreal strain of BCG. To this end, a study was made of the 
development of the Phipps strain of BCG in splenic tissue in comparison with 
that of the Montreal strain. 
6-wk old female NCS mice were obtained and divided into different groups. Actively grow- 
ing cultures of the two strains of BCG were used in this experiment. In either case, individuai RICHARD  COSTELLO  AND  TAKATERU  IZUMI  367 
animals received 0.2  ml of undiluted  7  day Tween-albumin culture  or the same volume of 
culture diluted 100-fold. The experimental findings are illustrated in Fig.  1. 
As may be seen,  the results obtained with the Phipps  strain vaccine were 
similar to those with the Montreal strain. The Phipps strain of BCG rapidly 
developed a  stable bacterial population in splenic tissue,  and the size of the 
ensuing population was determined by the size of the peritoneal inoculum. 
The original metabolic condition of the vaccine, i.e. whether in a  state  of 
active growth or not, had little noticeable effect on the results. As illustrated in 
Fig. 1, the development of freshly cultivated Montreal vaccine in the spleens of 
mice was essentially the same as that shown for lyophilized organisms in Table I. 
4,0  o 
.~  2.0 
e° r- 
}/ 
0 
BCG Montreal  BCG Phipps 
I  ""  i 
0.2 ml  cullure  0.2 ml  culture 
//  // 
Time  after infection (wk.) I re 
0  2  4  6 
FIG. 1. BCG organisms recovered from spleens of mice after peritoneal infection. Horizontal 
lines indicate sE of mean. 
Comparative Fate of BCG Organisms Injected by Different Routes.--The failure 
of peritoneally injected BCG to multiply within an animal's organs was studied 
in other experiments. Experiments comparing the effect of the route of vaccine 
administration  on the  ability  of BCG  to multiply in viva are  of particular 
interest in this respect. 
Female mice were used; they were 5-6 wk old when vaccinated. Vaccine was administered 
by the peritoneal, intravenous, or respiratory route. The same lot of lyophilized BCG (Mon- 
treal) was used in all cases. Typically, animals were intraperitoneally injected with 0.2 ml of 
suspension containing  104.8  BCG organisms, intravenously with 0.2  ml of suspension con- 
taining 10  a.7  bacilli, or by exposure to an aerosol prepared by nebulizing 105.5 organisms per 
ml over a 60 min period. The number of organisms present in the spleens and lungs of animals 
in each case was determined at intervals after infection. The results are given in Table II. 
As seen in Table II, BCG multiplied extensively in organs of animals given 
vaccine by the intravenous route. An average of 101"6 bacilli was recovered from 368  TUBERCULOSIS  RESISTANCE 
animals' spleens 24 hr after intravenous infection; the lungs retained even fewer 
organisms. By the following fortnight, however, the number of bacilli had in- 
creased  significantly in the  spleens and  in pulmonary tissue.  Multiplication 
continued in both organs through the 4th wk after infection. At this time, large 
numbers of bacilli were present in both organs. 6 wk after infection the number 
of BCG present in the animals' spleens and lungs had begun to recede. 
Vaccine organisms administered by aerosol also multiplied extensively  in vivo. 
TABLE II 
Multiplication  of BCG in  Organs of Mice  Vaccinated  by  Different  Routes 
Dose  Number of bacilli  present in organ*  Route of vaccine  (Viable units  Time after 
administration  per mouse)  infection  Spleen  Lung 
Intravenous  103 .7 
day  log  sD  log  sI) 
1  1.6  4-0.46  1.1  4-0.16 
14  3.0  4-1.22  1.4  4-0.64 
28  5.4  4-0.89  3.5  2=0.38 
42  4.1  4-0.45  3.0  4-1.01 
Aerosol  --:~  1§  0  --  0.7  -4-0.41 
14  0  --  1.6  :t=0.72 
28  0  --  4.3  4-0.48 
42  1.7  4-0.71  5.1  4-0.43 
Intraperitoneal  104. s  1  3.4  4-0.38  1.3  2=0.44 
14  3.0  4-0.36  0.7  4-0.51 
28  3.1  4-0.57  0.8  4-0.40 
42  2.2  4-0.40  0.1  (i/5) 
* No. of bacilli (log) present in 1 ml (out of total 5 ml) of organ homogenate at different 
times after infection with Montreal  strain BCG. Values in parenthesis  refer to number of 
organs positive out of total number tested.  Otherwise values are arithmetical  average for 
five organs. 
* Mice were exposed to the aerosol obtained by nebulizing 10 ml of suspension containing 
10 ~'5 BCG/ml over a 60 rain period. 
§ Time of sacrifice 60 min instead of 24 hr. 
Organisms were first recovered from pulmonary tissue in which  the vaccinal 
organisms grew profusely. They were also recovered from the spleen but only 
at a  later interval. The kinetics of BCG growth  after respiratory infection is 
given more fully in the following paper and will not be described in great detail 
here. 
The numbers of cultivable BCG organisms recovered from spleens and lungs 
of mice vaccinated by the peritoneal route did not increase significantly with 
time. Thus, as in the previous experiments, large numbers of bacilli were initially 
found in the animals' spleens, and fewer in the lungs. No significant change oc- RICHARD  COSTELLO  AND  TAKATERU  IZUMI  369 
curred in the vaccinal population of splenic tissue thereafter. The population of 
BCG  present  in  pulmonary tissue,  which  was  never  large,  steadily  declined 
throughout the experiment. 
Effect of Age and Diet.--The in vivo multiplication  of intraperitoneally  in- 
jected BCG was studied in mice of different ages maintained  on several nutri- 
tional regimes. 
Adult female mice were used in all cases. The age of the mice at the time of infection of 
vaccine varied from 5 to 40 wk. In other experiments, 5-wk old mice were fed either whole 
corn diets without  supplementation,  adequate  or inadequate  synthetic  diets, or commercial 
pellet rations. These diets were used for 3 wk before the administration  of BCG. The number 
of BCG bacilli present in the animals' spleens and lungs at intervals of time after infection was 
determined. 
The behavior of BCG was essentially the same in the organs of mice of the 
various  groups  studied.  As  in  the  experiments  previously described,  vaccine 
bacilli were rapidly taken up by the animals' spleens and lungs after peritoneal 
injection.  They  persisted  in  splenic  tissue  without  overt  multiplication  and 
slowly declined  in pulmonary tissue.  Neither  the animals'  age nor its dietary 
history significantly altered the course of the vaccinating infection. 
Massive Intravenous Challenge.--The  results just mentioned indicate that the 
number of viable bacilli present in the lungs and spleens of mice injected intra- 
peritoneally with BCG is largely determined by the size of the vaccinating dose, 
It seemed useful to test whether the degree of resistance acquired by mice after 
intraperitoneal injection of BCG was also determined by the amount of vaccine 
administered. 
For these experiments the simple survival test described by Donovick et al. 
was utilized (6). A  typical experiment will serve to illustrate the techniques in- 
volved with this test. 
4-wk old female  mice were randomly divided  into groups  of 20  mice. Representative 
groups of animals were vaccinated by peritoneal  injection of BCG. To this end, the Montreal 
strain  of BCG was subcultured  in Tween-albumin  medium for 7 days.  Serial dilutions  of 
growth were made in albumin water and individual animals received 0.2 ml of diluted culture. 
27 days later these animals, and also comparable untreated mice, were challenged by super- 
infection of 0.2 ml of virulent human bacilli administered intravenously. The results are given 
in Table III. 
Unvaccinated  animals  began  to  die  11  days  after  challenge  infection.  All 
animals in this group succumbed to the infection within a fortnight. The average 
survival time was 15 days. 
All vaccinated animals exhibited some protection against the lethal effects of 
challenge.  The  degree  of protection,  however,  was  largely dependent  on  the 
amount of vaccine that the animals had received. 
Animals receiving the largest quantity of vaccine were most highly protected: 370  TUBERCULOSIS  RESISTANCE 
Only a few of them died during the first 30 days after challenge; deaths occurred 
infrequently  thereafter  and  one animal  of this  group was still alive when  the 
experiment  was terminated  after  120 days.  In contrast,  the majority of mice 
receiving the lowest dose of vaccine died within the first 30 days after challenge 
infection. The susceptibility of these mice was little different from that of un- 
treated  mice.  A  few animals  in  this  group,  however,  exhibited  significant re- 
sistance  against  the  lethal  effects of the  challenge  infection.  The life of these 
protected  animals  was prolonged almost as much as for the majority of mice 
receiving the larger immunizing dose. Animals receiving intermediate  doses of 
vaccine attained a higher degree of protection than animals receiving the lowest 
quantity  of vaccine but a  lower degree of protection  than  those receiving  the 
TABLE III 
E~rect of Vaccination on the  Survival  Time  of Swiss Albino Mice 
Intravenously  Challenged  with  H37Rv 
No. of deaths:~ 
Vaccine  Amount of vaccine  No. of  Average  survival 
injected*  mice  before  20-30  30-40  40-50  50-75  75-100  >100  time 
20 
ml 
None  diluent  17  15  2  -- 
BCG  0.2  X  10  -4  17  7  2  1 
0.2  X  10  -3  17  4  3  1 
0.2  X  10  -2  18  4  1  0 
0.2  X  10  -1  16  1  2  0 
days 
15 
4  2  0  1  21 
3  4  0  2  31 
6  3  4  --  41 
5  6  1  1  47 
* Montreal  strain  of BCG administered  by intraperitoneal  injection. 
:~ Mice dead in period of time  (days) after  intravenous  injection  of 0.2 ml of undiluted 
culture  of M.  turberculosis. 
largest amount of BCG. This relative  immunity is shown in Figs.  2 a  and 2 b 
where  the  mortality  data  are  graphically  plotted. 
Fig. 2 a  shows the percentage of animals that died of tuberculous disease at 
given intervals  after  challenge.  Actual graph points of individual  animals  are 
given only for the control group and for the group receiving the largest quantity 
of vaccine. Fig. 2 b presents  the same data as a  probit graph. The latter graph 
shows that not only was the average survival time  of mice prolonged by vac- 
cination, but also that the kinetic rate of the mortality reaction was significantly 
altered. This is especially noticeable for mice receiving suboptimal quantities of 
vaccine. 
It should be noted, however,  that the differences are due almost entirely to 
the fact  that many of the mice in  the  latter  groups were  unprotected.  Thus, 
53 %  of the animals receiving the smallest quantity of vaccine died in an acute 
manner  (10)  before the 30th day of infection and therefore can be considered RICHARD COSTELLO AND  TAKATERU  IZUMI  371 
to be nonimmune.  Of the animals which received the next three dilutions of 
BCG, 41, 28, and 19% were also apparently not immunized. 
For  comparative purposes,  these  animals  were  removed from  the  experi- 
mental data and the survival curve for the remaining vaccinated mice (those 
G orgonisms 
~g 
Eg 
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CL  S 
I00  I  i  i  i  i  I  2o  20  6'o  8'o  IOO  12o 
Time ofter chGllenge infection (doys) 
FIG.  2  a.  Deaths of vaccinated and control NCS mice after intravenous infection with 
virulent human bacilli. 
"~  20  104.6 BCG  Organisms  J~ 
u  50 
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o  50 
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FIG. 2 b. Deaths of vaccinated and control NCS mice after intravenous challenge infection 
recorded as logarithmic probability. 372  TUBERCULOSIS  RESISTANCE 
that died after the 30th day) was replotted. This plot is shown in Fig. 2 c, which 
shows that there was little apparent difference in the average survival time of 
such immune animals. 
Vaccination  Time.--The  length of time between vaccination and challenge 
was increased from 27 to 56 days to allow for any effect due to the in vivo multi- 
plication of the vaccine bacilli. This change, however, did not affect the results. 
The degree of protection afforded by vaccination was again found to be directly 
proportional to the  quantity  of BCG  initially injected. As  in  the preceding 
experiment, a relatively larger percentage of mice given the larger amounts of 
vaccine were protected. There were no large differences in the mean survival 
time of protected animals within the different groups. 
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FIG. 2 c. Deaths of immune mice after intravenous challenge  infection.  See text for explana- 
tion. 
DISCUSSION 
Animals vaccinated with living BCG by the peritoneal route were significantly 
more resistant to the lethal effects of intravenously injected mycobacteria than 
were untreated animals. Moreover, the degree of resistance elicited by vaccina- 
tion was directly related to the quantity of vaccine administered to the animal. 
Previous studies from this laboratory have revealed that when the amount of 
BCG injected intravenously into mice is small, the induction of antitubercular 
immunity depends upon the multiplication of the vaccine in vivo (11-13). In 
contrast, when the vaccinal dose injected intravenously is very large, the amount 
of bacterial protoplasm injected provides outright an antigenic mass sufficient 
to elicit a high level of antitubercular resistance. 
The experimental results reported in the present paper extend these findings. 
It was found that the ultimate vaccinal population which develops within the 
organs of mice given BCG by the intraperitoneal route is directly proportional 
to the initial size of the vaccinating dose. Animals intraperitoneally vaccinated RICHARD  COSTELLO  AND  TAKATERU IZUMI  373 
with large quantities of BCG develop a large population of BCG in their organs 
and  are  highly protected  against tubercular mortality; in  contrast,  animals 
given smaller quantities of vaccine exhibit but limited numbers of BCG in their 
organs and develop little antitubercular resistance. 
It must be emphasized, however, that these findings apply only with regard 
to the level of protection achieved by each group of mice taken as a whole. 
Individual animals vaccinated with suboptimal quantities of BCG respond to 
the challenge infection in two separate ways. On the one hand, some animals 
exhibit significant resistance to the lethal effects of the challenge infection, on 
the other hand, some exhibit little or no protective response. 
It should be noted in this regard that Swiss strain mice are not highly inbred. 
Therefore, it is possible that some variation may occur in the relative sensitivity 
of different animals to immunization. Nonetheless, it seems unlikely that this 
explanation can totally account for the results reported here. 
The failure of BCG to multiply within the animal's organs after its peritoneal 
administration is of especial interest and deserves comment. It is well known 
that strains of BCG differ widely in their ability to grow within an animal's 
tissues (14, 15). However, the two strains of BCG utilized in this study, namely 
the Montreal and the Phipps strain, have consistently been found to multiply 
entensively in vivo. Moreover, as reported here, both strains grow extensively 
within an animal's tissues when the vaccine is administered by the intravenous 
or the respiratory route. There is no way at present to account for the tubercu- 
lostasis which occurs in splenic tissue following peritoneal injection. Material in- 
jected into the peritoneum is rapidly removed via the diaphragmatic lymphatics 
(16) and reaches the animal's bloodstream within minutes after its administra- 
tion. Moreover, BCG is as rapidly taken up by the animal's organs after peri- 
toneal injection as it is after intravenous administration. Yet BCG organisms, 
given by the peritoneal route, fail to multiply in either spleen or lung tissue, 
whereas the same material injected directly into the bloodstream multiplies 
extensively in both organs. 
Other investigators have noted that large doses of intravenously administered 
BCG fail to multiply within an animal's tissues, whereas smaller quantities of 
vaccine grow profusely (17).  It is probable that, after administration of large 
quantities of BCG, a state of acquired resistance is rapidly initiated and that 
subsequent  multiplication  of  the  vaccinating  organisms  is  thereby  limited. 
Whether a similar type of infection immunity is initiated after the peritoneal 
injection of smaller quantities of BCG cannot be said. It is worth mentioning 
in this respect, however, that the immune resistance of splenic tissue has been 
found to be rapidly established.  2 It would appear that the rapid vaccinal dor- 
mancy achieved by peritoneally injected mycobacteria might be a useful tool 
in elucidating the theoretical and practical basis of infection or premunition 
immunity. 
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SUMMARY 
Enhanced  resistance  against  experimental  tuberculosis  was  acquired  by 
albino mice after peritoneal vaccination with living BCG. 
Prolongation  of  life was  used  as  a  measure  of  resistance  against massive 
intravenous challenge infection. The average degree of prolongation of life was 
found to be directly related to the size of the vaccinating dose. The ultimate 
numbers of BCG bacilli recovered from the animal's organs were also directly 
related to the quantity of vaccine initially administered. It appears therefore 
that  the  relative degree  of antitubercular resistance  achieved  by immunized 
mice is closely related to the vaccinal population present in the animal's organs. 
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